221 related articles for article (PubMed ID: 10480007)
21. Selective estrogen receptor modulators: a new category of compounds to extend postmenopausal women's health.
Goldstein SR
Int J Fertil Womens Med; 1999; 44(5):221-6. PubMed ID: 10569450
[TBL] [Abstract][Full Text] [Related]
22. Sentinel lymph node biopsy for breast cancer.
Swanson JO
J Insur Med; 2001; 33(2):195-7. PubMed ID: 11510518
[TBL] [Abstract][Full Text] [Related]
23. Tamoxifen in ductal carcinoma in situ.
Daly MB
Semin Oncol; 2006 Dec; 33(6):647-9. PubMed ID: 17145343
[TBL] [Abstract][Full Text] [Related]
24. I am 51 years old, perimenopausal, have irritable bowel syndrome and a family history of breast cancer, and am told my bones are thinning. These conditions would seem to rule out my use of estrogen or Fosamax. I weight train and take 1,500 mg of calcium a day to stave off osteoporosis. What's left?
Robb-Nicholson C
Harv Womens Health Watch; 1998 Nov; 6(3):8. PubMed ID: 9814138
[No Abstract] [Full Text] [Related]
25. [New developments in the hormonal treatment of breast cancer in postmenopausal women].
Trunet P; Marty M
Bull Cancer; 1999 Oct; 86(10):815-20. PubMed ID: 10572232
[TBL] [Abstract][Full Text] [Related]
26. A new alternative to estrogen: raloxifene.
Runowicz C
Health News; 1998 Jun; 4(8):4. PubMed ID: 9644506
[No Abstract] [Full Text] [Related]
27. Raloxifene for postmenopausal osteoporosis.
Med Lett Drugs Ther; 1998 Mar; 40(1022):29-30. PubMed ID: 9529516
[No Abstract] [Full Text] [Related]
28. Status of antiestrogen breast cancer prevention trials.
Powles TJ
Oncology (Williston Park); 1998 Mar; 12(3 Suppl 5):28-31. PubMed ID: 9556788
[TBL] [Abstract][Full Text] [Related]
29. Raloxifene: a selective estrogen receptor modulator.
Scott JA; Da Camara CC; Early JE
Am Fam Physician; 1999 Sep; 60(4):1131-9. PubMed ID: 10507743
[TBL] [Abstract][Full Text] [Related]
30. Breast cancer biology blossoms in the clinic.
Nass SJ; Hahm HA; Davidson NE
Nat Med; 1998 Jul; 4(7):761-2. PubMed ID: 9662357
[No Abstract] [Full Text] [Related]
31. SERMs: meeting the promise of multifunctional medicines.
Jordan VC
J Natl Cancer Inst; 2007 Mar; 99(5):350-6. PubMed ID: 17341726
[TBL] [Abstract][Full Text] [Related]
32. Clear thinking on tamoxifen.
Johns Hopkins Med Lett Health After 50; 1998 Jul; 10(5):1-2. PubMed ID: 9650523
[No Abstract] [Full Text] [Related]
33. Biomonitoring of urinary tamoxifen and its metabolites from breast cancer patients using nonaqueous capillary electrophoresis with electrospray mass spectrometry.
Carter SJ; Li XF; Mackey JR; Modi S; Hanson J; Dovichi NJ
Electrophoresis; 2001 Aug; 22(13):2730-6. PubMed ID: 11545399
[TBL] [Abstract][Full Text] [Related]
34. Effects of raloxifene in postmenopausal women.
Friedman MN
N Engl J Med; 1998 Apr; 338(18):1313; author reply 1313-4. PubMed ID: 9565493
[No Abstract] [Full Text] [Related]
35. [Agonists-antagonists of estrogens, their potential use in prophylaxis and treatment of osteoporosis].
Hoszowski K
Pol Tyg Lek; 1995 Nov; 50(44-47):41-2. PubMed ID: 8643425
[TBL] [Abstract][Full Text] [Related]
36. Mechanisms of tamoxifen resistance.
Ring A; Dowsett M
Endocr Relat Cancer; 2004 Dec; 11(4):643-58. PubMed ID: 15613444
[TBL] [Abstract][Full Text] [Related]
37. Tamoxifen in premalignant and pre-invasive breast cancer.
Neven P
Eur J Cancer Prev; 1993 Nov; 2 Suppl 3():147-51. PubMed ID: 8298445
[No Abstract] [Full Text] [Related]
38. New drug approved to help prevent osteoporosis.
Mayo Clin Health Lett; 1998 Mar; 16(3):3. PubMed ID: 9516369
[No Abstract] [Full Text] [Related]
39. Endocrine therapy for early breast cancer.
Hussain SA; Williams S; Stevens A; Rea DW
Expert Rev Anticancer Ther; 2004 Oct; 4(5):877-88. PubMed ID: 15485321
[TBL] [Abstract][Full Text] [Related]
40. [Antiestrogens: mechanism of action and clinical applications].
Barrón-González A; Arias-Martínez J; Castro-Romero I
Salud Publica Mex; 2001; 43(6):577-84. PubMed ID: 11816234
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
